Synonyms: AMR-69 | Esbriet®
pirfenidone is an approved drug (EMA (2011), FDA (2014))
Compound class:
Synthetic organic
Comment: Pirfenidone is an anti-fibrotic drug. In addition to its proven anti-fibrotic effects in lung tissue, pirfenidone-induced in vitro and in vivo anti-fibrotic activity has been reported in experimental liver and renal fibrosis [3,5].
SARS-CoV-2: COVID-19 is accompanied by inflammation and fibrotic lung damage that appears to persist beyond immediate recovery. The clinical potential for applying the antifibrotic activity of pirfenidone to help treat COVID-19-related pulmonary fibrosis is reviewed by Ferrara et al. (2020) [2]. |
|
References |
1. Conte E, Gili E, Fagone E, Fruciano M, Iemmolo M, Vancheri C. (2014)
Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci, 58: 13-9. [PMID:24613900] |
2. Ferrara F, Granata G, Pelliccia C, La Porta R, Vitiello E. (2020)
The added value of pirfenidone to fight inflammation and fibrotic state induced by SARS-CoV-2. European Journal of Clinical Pharmacology,. DOI: 10.1007/s00228-020-02947-4 |
3. García L, Hernández I, Sandoval A, Salazar A, Garcia J, Vera J, Grijalva G, Muriel P, Margolin S, Armendariz-Borunda J. (2002)
Pirfenidone effectively reverses experimental liver fibrosis. J Hepatol, 37 (6): 797-805. [PMID:12445421] |
4. King Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L et al.. (2014)
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med, 370 (22): 2083-92. [PMID:24836312] |
5. Macías-Barragán J, Sandoval-Rodríguez A, Navarro-Partida J, Armendáriz-Borunda J. (2010)
The multifaceted role of pirfenidone and its novel targets. Fibrogenesis Tissue Repair, 3: 16. [PMID:20809935] |